America Great Health (AAGH)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
America Great Health (AAGH) with AI Score 56/100 (Hold). America Great Health is a biotechnology company focused on researching and developing protein and peptide small molecular drugs. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026America Great Health (AAGH) Healthcare & Pipeline Overview
America Great Health, a biotechnology company established in 2013, focuses on the research and development of protein and peptide small molecular drugs, alongside manufacturing AI cloud computing-based diagnostic devices, cell therapies, and regenerative medicine, positioning itself within the competitive healthcare sector.
Investment Thesis
America Great Health presents a high-risk, high-reward investment opportunity within the biotechnology sector. Key value drivers include the successful development and commercialization of its protein and peptide small molecular drugs, as well as the adoption of its AI cloud computing-based diagnostic devices. The company's focus on cell therapy and regenerative medicine also offers long-term growth potential. However, the company's negative profit margin of -173.0% and high beta of 6.35 indicate significant financial risks. The absence of a dividend further reduces its attractiveness to income-seeking investors. Upcoming catalysts include potential breakthroughs in its drug development pipeline and partnerships for its AI-based diagnostic devices. Investors should carefully consider the company's financial stability and the competitive landscape before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- America Great Health operates with a small team of 5 employees, indicating a lean operational structure.
- The company's negative P/E ratio of -4.26 reflects its current lack of profitability.
- AAGH's profit margin of -173.0% highlights significant financial challenges and operational inefficiencies.
- The company boasts a high gross margin of 91.1%, suggesting strong pricing power on its existing products.
- AAGH's high beta of 6.35 indicates substantial volatility compared to the overall market.
Competitors & Peers
Strengths
- Focus on innovative technologies like AI and cell therapy.
- High gross margin of 91.1% indicates strong pricing power.
- Potential for breakthrough discoveries in drug development.
- Established presence in the health and wellness supplement market.
Weaknesses
- Negative profit margin of -173.0% indicates financial instability.
- Small team of 5 employees limits operational capacity.
- Limited financial resources for research and development.
- High beta of 6.35 indicates significant market volatility.
Catalysts
- Upcoming: Potential breakthroughs in the development of protein and peptide small molecular drugs.
- Upcoming: Successful clinical trials and regulatory approvals for new drugs and devices.
- Ongoing: Expansion of AI-based diagnostic devices in the healthcare sector.
- Ongoing: Strategic partnerships and collaborations with larger companies.
- Ongoing: Growth in the cell therapy and regenerative medicine market.
Risks
- Potential: Intense competition in the biotechnology and pharmaceutical industries.
- Potential: Regulatory hurdles and lengthy approval processes for new drugs and devices.
- Potential: Patent expiration and generic competition.
- Ongoing: Negative profit margin of -173.0% indicates financial instability.
- Ongoing: Limited financial resources for research and development.
Growth Opportunities
- Expansion of AI-Based Diagnostic Devices: The market for AI in healthcare diagnostics is projected to reach $6.7 billion by 2026, offering a significant growth opportunity for America Great Health. By leveraging its AI cloud computing-based diagnostic devices, the company can tap into this growing market. Successful development and commercialization of these devices could drive revenue growth and improve profitability. Timeline: Ongoing.
- Development of Protein and Peptide Small Molecular Drugs: The global market for peptide therapeutics is expected to reach $41.8 billion by 2028. America Great Health's focus on researching and developing protein and peptide small molecular drugs positions it to capitalize on this growing market. Successful clinical trials and regulatory approvals could lead to significant revenue streams. Timeline: Ongoing.
- Cell Therapy and Regenerative Medicine: The regenerative medicine market is projected to reach $53.6 billion by 2025. America Great Health's involvement in cell therapy and regenerative medicine offers long-term growth potential. Advances in these fields could lead to breakthrough treatments for various diseases and conditions. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers can accelerate the development and commercialization of America Great Health's products. Collaborations can provide access to funding, expertise, and distribution channels. Timeline: Ongoing.
- Expansion into International Markets: Expanding into international markets, particularly in Asia and Europe, can broaden America Great Health's customer base and revenue streams. Adapting its products and services to meet the needs of different markets can drive growth. Timeline: Ongoing.
Opportunities
- Expansion of AI-based diagnostic devices in the healthcare sector.
- Development and commercialization of protein and peptide small molecular drugs.
- Growth in the cell therapy and regenerative medicine market.
- Strategic partnerships and collaborations with larger companies.
Threats
- Intense competition in the biotechnology and pharmaceutical industries.
- Regulatory hurdles and lengthy approval processes for new drugs and devices.
- Patent expiration and generic competition.
- Economic downturns and reduced healthcare spending.
Competitive Advantages
- Proprietary AI cloud computing-based diagnostic technology.
- Intellectual property related to protein and peptide small molecular drugs.
- Expertise in cell therapy and regenerative medicine.
- Established brand reputation in the health and wellness supplement market.
About AAGH
America Great Health, founded in 2013 and headquartered in Alhambra, California, operates as a biotechnology company focused on the research, development, and manufacturing of innovative healthcare solutions. Originally known as Crown Marketing, the company transitioned to America Great Health in March 2017, signaling a strategic shift towards biotechnology. The company's core activities include the research and development of protein and peptide small molecular drugs, targeting various therapeutic areas. Additionally, America Great Health manufactures and sells AI cloud computing-based diagnostic and medical devices, leveraging artificial intelligence to enhance diagnostic accuracy and efficiency. The company is also involved in cell therapy and regenerative medicine, exploring advanced treatments for various diseases and conditions. Furthermore, America Great Health offers a range of supplements, catering to the growing demand for health and wellness products. With a small team of 5 employees, the company focuses on innovation and technological advancement within the biotechnology sector.
What They Do
- Researches and develops protein and peptide small molecular drugs.
- Manufactures and sells AI cloud computing-based diagnostic and medical devices.
- Engages in cell therapy research and development.
- Develops regenerative medicine technologies.
- Offers a range of health and wellness supplements.
- Leverages AI to enhance diagnostic accuracy and efficiency.
Business Model
- Generates revenue through the sale of AI cloud computing-based diagnostic and medical devices.
- Seeks to generate revenue through the sale of protein and peptide small molecular drugs upon successful development and regulatory approval.
- Aims to generate revenue from cell therapy and regenerative medicine products and services.
- Generates revenue through the sale of supplements.
Industry Context
America Great Health operates within the dynamic and competitive biotechnology industry, characterized by rapid innovation and evolving market trends. The industry is driven by advancements in genomics, proteomics, and personalized medicine. The market for AI-based diagnostic devices is experiencing significant growth, fueled by the increasing adoption of artificial intelligence in healthcare. Competitors like ADXS, AGNPF, AGTX, APLIF, and HESG are also vying for market share in the biotechnology and pharmaceutical sectors. America Great Health's success depends on its ability to differentiate itself through innovative products and strategic partnerships.
Key Customers
- Hospitals and clinics utilizing AI-based diagnostic devices.
- Research institutions involved in drug development and clinical trials.
- Patients seeking cell therapy and regenerative medicine treatments.
- Consumers purchasing health and wellness supplements.
Financials
Chart & Info
America Great Health (AAGH) stock price: Price data unavailable
Latest News
No recent news available for AAGH.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AAGH.
Price Targets
Wall Street price target analysis for AAGH.
MoonshotScore
What does this score mean?
The MoonshotScore rates AAGH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mike Qingkun Wang
CEO
Mike Qingkun Wang is the CEO of America Great Health, leading a team of 5 employees. His background includes experience in managing small teams and guiding the strategic direction of the company. He has overseen the company's transition from Crown Marketing to America Great Health, focusing on biotechnology and healthcare solutions. His leadership is crucial in driving the company's research and development efforts and commercialization strategies.
Track Record: Under Mike Qingkun Wang's leadership, America Great Health has focused on developing AI cloud computing-based diagnostic devices and exploring cell therapy and regenerative medicine. He has guided the company's efforts in researching and developing protein and peptide small molecular drugs. His strategic decisions have shaped the company's direction in the biotechnology sector.
AAGH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that America Great Health may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- Low trading volume and liquidity.
- High volatility and price swings.
- Risk of delisting or suspension from the OTC market.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Company has been in operation since 2013.
- Focus on research and development in the biotechnology sector.
- Development of AI cloud computing-based diagnostic devices.
- Headquartered in Alhambra, California.
America Great Health Stock: Key Questions Answered
What does America Great Health do?
America Great Health operates as a biotechnology company focused on the research, development, and manufacturing of innovative healthcare solutions. The company's core activities include the research and development of protein and peptide small molecular drugs, targeting various therapeutic areas. Additionally, America Great Health manufactures and sells AI cloud computing-based diagnostic and medical devices, leveraging artificial intelligence to enhance diagnostic accuracy and efficiency. The company is also involved in cell therapy and regenerative medicine, exploring advanced treatments for various diseases and conditions. Furthermore, America Great Health offers a range of supplements, catering to the growing demand for health and wellness products.
What do analysts say about AAGH stock?
Currently, there is no available analyst coverage for America Great Health (AAGH) due to its OTC listing and small market capitalization. Key valuation metrics such as price targets and ratings are not available. Investors should conduct their own thorough research and due diligence before considering an investment in AAGH. Factors to consider include the company's financial performance, growth prospects, and the risks associated with investing in OTC stocks. The absence of analyst coverage underscores the need for independent assessment and caution.
What are the main risks for AAGH?
Investing in America Great Health carries significant risks, primarily stemming from its OTC listing and financial instability. The company's negative profit margin of -173.0% and high beta of 6.35 indicate substantial financial challenges and market volatility. Limited financial disclosure and transparency on the OTC market increase the risk of fraud or manipulation. Regulatory hurdles and lengthy approval processes for new drugs and devices pose additional challenges. Competition in the biotechnology and pharmaceutical industries is intense, and patent expiration could impact future revenue streams.
What are the key factors to evaluate for AAGH?
America Great Health (AAGH) currently holds an AI score of 56/100, indicating moderate score. Key strength: Focus on innovative technologies like AI and cell therapy.. Primary risk to monitor: Potential: Intense competition in the biotechnology and pharmaceutical industries.. This is not financial advice.
How frequently does AAGH data refresh on this page?
AAGH prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AAGH's recent stock price performance?
Recent price movement in America Great Health (AAGH) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on innovative technologies like AI and cell therapy.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AAGH overvalued or undervalued right now?
Determining whether America Great Health (AAGH) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AAGH?
Before investing in America Great Health (AAGH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be limited or unreliable.
- Financial data based on available information and may not be comprehensive.
- AI analysis pending.